Technology
Health
Biotechnology

NewLink Genetics

$1.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.52%) Today
-$0.01 (-0.52%) Today

Why Robinhood?

You can buy or sell NLNK and other stocks, options, ETFs, and crypto commission-free!

About

NewLink Genetics Corporation Common Stock, also called NewLink Genetics, is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Read More The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Employees
55
Headquarters
Ames, Iowa
Founded
1999
Market Cap
71.15M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
621.66K
High Today
$1.92
Low Today
$1.82
Open Price
$1.92
Volume
186.04K
52 Week High
$7.77
52 Week Low
$1.28

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
US
North America

News

MarketBeatMar 5

Stock Price, News, & Analysis for NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer.

96
Simply Wall StMar 2

NewLink Genetics Corporation (NASDAQ:NLNK): Is It A Good Long Term Opportunity?

The latest earnings release NewLink Genetics Corporation’s (NASDAQ:NLNK) announced in December 2018 showed company earnings became less negative compared to the previous year’s level – great news for investors Below is a brief commentary on my key takeaways on how market analysts perceive NewLink Genetics’s earnings growth trajectory over the next few years and whether the future looks brighter.

64

Earnings

-$0.77
-$0.58
-$0.39
-$0.20
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 2, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.